Project Number 3R01AG058660-03S1A1 Agency/Funding Organization NIA Funding Year 2021 View Full Project Details for A Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Phase II Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Mild to Moderate Alzheimerʼs Disease Research Categorization Primary Disease / Condition Alzheimer's Disease CADRO Category C. Translational Research and Clinical Interventions 7. Early-stage Clinical Drug Development (Phase I and II Clinical Trials) a. Amyloid beta Researcher and Organization Principal Investigator CATALANO, SUSAN M Principal Investigator First Name SUSAN Principal Investigator Last Name CATALANO Awardee Organization Cognition Therapeutics, Inc. Awardee State Pennsylvania Contact PI Country United States Project Detail Funding Opportunity Announcement PAR-18-877: Early Stage Clinical Trials for the Spectrum of Alzheimers Disease and Age-related Cognitive Decline (R01 Clinical Trial Optional) FY Overall Cost $13,634,548 Funding Organization Agency/Funding Organization NIA Funding Organization Country United States Program Official RYAN, LAURIE M
